News

Sagnieres’ chairman and CEO position will be effective from 2 January 2012. Since 1 January 2010, Hubert Sagnieres has served at Essilor as CEO and chief operating officer

The Drugs of Abuse Array V (DoA V) will enable detection of eight designer drugs and their metabolites within a single undivided specimen. The panel targets Methcathinone, Mephedrone,

Under the acquisition, Bellwyck’s Healthcare Division operates Ontario – based Ace which provides solid dose primary and secondary packaging to over the counter (OTC) and prescription pharmaceuticals. Pharmaceuticals

LSDs which are inherited metabolic disorders can be treated with an enzyme replacement therapy (ERT). biOasis and Shire’s scientists will jointly collaborate to evaluate the potential of Transcend

According to the company, the transaction is expected to close in a span of five or six months. Transgene Biotek managing director KK Rao said the deal would

SYN118 is a potent and selective inhibitor of 4-hydroxyphenylpyruvate dioxygenase (HPPD), which is an enzyme in the primary pathway responsible for the breakdown of tyrosine, the precursor of

According to the company, the products are likely to complete their phase III trials by early 2014, facilitating the launch, news.in.msn.com reports. The Phase II trials are expected

The second tranche included $21.4m in equity financing from Radius’ current investors and $6.25 million in debt financing from GE Capital, Healthcare Financial Services and Oxford Finance. The

The company plans to market the product to treat severe, nodular acne, following approval. Cip-Isotretinoin uses Lidose drug delivery system, which delivers more consistent bioavailability for relatively water-insoluble